尽管报告出现亏损,但由于投资者需求强,Turn Therapeutics在2025年10月8日首次公开募股后的股价升了134%. Turn Therapeutics' stock surged 134% after its IPO debut on October 8, 2025, driven by strong investor demand despite a reported loss.

在纳斯达克首次亮相之后,Turn Therapeutics (TTRX) 在2025年10月8日的下午交易中升134.29%,至16.40美元,尽管常规交易日收盘在7.00美元. Turn Therapeutics (TTRX) surged 134.29% to $16.40 in after-hours trading on October 8, 2025, following its Nasdaq debut, despite closing the regular session at $7.00. 这家生物技术公司通过投资促进组织公诸于众,看到投资者的强烈兴趣驱动这次集会,尽管它报告每股损失0.04美元,没有红利。 The biotech company, which went public via an IPO, saw strong investor interest driving the rally, though it reported a loss of $0.04 per share and has no dividend. 股票存量达到52周的最高点,为10 000美元,市场上限为4.5957亿美元。 The stock reached a 52-week high of $10.00 and has a market cap of $459.57 million. 这一激增反映了生物技术部门更广泛的势头,在对即将到来的临床数据和产品推出持乐观态度的情况下,一些保健库存在上升。 The surge reflects broader momentum in the biotech sector, with several healthcare stocks rising amid optimism over upcoming clinical data and product launches.